Peter Blume-Jensen - 01 Mar 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Signature
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol
ACRV
Transactions as of
01 Mar 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 16:15:29 UTC
Previous filing
24 Feb 2026

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Blume-Jensen Peter President and CEO, Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen 03 Mar 2026 0001950499
Masson Kristina EVP - Business Operations, Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson 03 Mar 2026 0001950501

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +417,210 $0.000000 417,210 01 Mar 2026 Common Stock 417,210 $1.51 Direct F1, F2
transaction ACRV Stock Option (Right to Buy) Award $0 +185,495 $0.000000 185,495 01 Mar 2026 Common Stock 185,495 $1.51 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.